Fig 4 highlights the important, and patient-specific, role that b3 may play in further efforts to deploy (8)–(11) for the modeling of Alzheimer’s disease. In particular values of b3 ≈ 1 do lead to the development of tauopathy; however, this development emerges significantly later than for higher values of this interaction parameter. Clinically, such a value of b3 could correspond to a patient who, at the time of death, presents significant amyloid plaques but negligible, or undetectable, levels of neurofibrillary tau tangles. The gene discussed is MAPT; the disease is tauopathy.